GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » Cash Flow from Financing

Orion Infusions (DHA:ORIONINFU) Cash Flow from Financing : BDT-8.4 Mil (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Orion Infusions Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Orion Infusions paid BDT0.0 Mil more to buy back shares than it received from issuing new shares. It spent BDT10.6 Mil paying down its debt. It paid BDT0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent BDT0.0 Mil paying cash dividends to shareholders. It spent BDT2.9 Mil on other financial activities. In all, Orion Infusions spent BDT13.5 Mil on financial activities for the three months ended in Dec. 2023.


Orion Infusions Cash Flow from Financing Historical Data

The historical data trend for Orion Infusions's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions Cash Flow from Financing Chart

Orion Infusions Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.43 -41.94 -73.32 -2.78 19.29

Orion Infusions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.69 -22.61 41.45 -13.73 -13.53

Orion Infusions Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Orion Infusions's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Orion Infusions's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-8.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions  (DHA:ORIONINFU) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Orion Infusions's issuance of stock for the three months ended in Dec. 2023 was BDT0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Orion Infusions's repurchase of stock for the three months ended in Dec. 2023 was BDT0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Orion Infusions's net issuance of debt for the three months ended in Dec. 2023 was BDT-10.6 Mil. Orion Infusions spent BDT10.6 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Orion Infusions's net issuance of preferred for the three months ended in Dec. 2023 was BDT0.0 Mil. Orion Infusions paid BDT0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Orion Infusions's cash flow for dividends for the three months ended in Dec. 2023 was BDT-0.0 Mil. Orion Infusions spent BDT0.0 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Orion Infusions's other financing for the three months ended in Dec. 2023 was BDT-2.9 Mil. Orion Infusions spent BDT2.9 Mil on other financial activities.


Orion Infusions Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Orion Infusions's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions (DHA:ORIONINFU) Business Description

Traded in Other Exchanges
N/A
Address
Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines